Sequence requirements of ATF2 and CREB binding to the human T-cell leukemia virus type 1 LTR R region.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Sequence requirements of ATF2 and CREB binding to the human T-cell leukemia virus type 1 LTR R region.

Virology. 1996 Apr 15;218(2):362-71. Unique Identifier : AIDSLINE MED/96193748
Xu X; Kang SH; Heidenreich O; Brown DA; Nerenberg MI; Department of Molecular and Experimental Medicine, Scripps; Research Institute, La Jolla, California 92037, USA.

Abstract: We have identified crucial transcription factor contact sites within the distal portion of the HTLV-1 LTR R region. Single base substitutions within this region greatly reduce formation of a complex which we previously described as a 70-kDa nuclear protein interacting with a CREB-like protein. Comparison of published sequences of HTLV-1 isolates obtained from scattered geographic locations revealed that clustered mutations in an 8-base segment near the U5 junction do, in fact, occur naturally. A single base substitution corresponding to a common naturally occurring mutation was introduced into the R region of an HTLV-1-LTR Cat construct. This resulted in derepression of the promoter in a cell line expressing high levels of the R region binding complex when compared to the wild-type LTR promoter. Affinity purification and electrophoretic mobility super-shift analysis identified a dominant 70-kDa DNA binding protein as ATF-2. Phosphorylated ATF-2 apparently interacts with CREB to form this downstream complex.

Keywords: Base Sequence DNA Mutational Analysis DNA-Binding Protein, Cyclic AMP-Responsive/CHEMISTRY/*METABOLISM DNA, Viral/*GENETICS/METABOLISM Human HTLV-I/*GENETICS HTLV-I Infections/VIROLOGY Methylation Molecular Sequence Data Molecular Weight Phosphorylation Point Mutation/GENETICS Promoter Regions (Genetics)/GENETICS Protein Binding Repetitive Sequences, Nucleic Acid/*GENETICS Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Transcription Factors/CHEMISTRY/*METABOLISM JOURNAL ARTICLE
960830
M9681131

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .